Aceta Extend Tablet (Extended Release) 665 mg

Aceta Extend Tablet (Extended Release), manufactured by Biopharma Limited, is a trusted extended-release formulation containing 665 mg of paracetamol. Designed for prolonged analgesic and antipyretic effects, it reduces dosing frequency while maintaining therapeutic efficacy.

Priced at ৳2.00 per unit (৳20.00 per strip), this cost-effective solution treats diverse conditions: fever, migraines, dental pain, osteoarthritis, and post-vaccination discomfort. Its extended-release technology ensures steady medication release over 8 hours, ideal for chronic pain management.

Adults and children above 12 years may take two tablets every 8 hours, not exceeding six tablets daily. Unlike immediate-release variants, this 665 mg formulation minimizes peak-trough fluctuations, enhancing patient compliance. Caution: Avoid alcohol to prevent hepatotoxicity.

Common side effects include rare skin rashes or pancreatic inflammation. Severe overdose (≥10g) risks liver damage, requiring immediate N-acetylcysteine treatment. Consult doctors when using with anticonvulsants or tuberculosis medications due to metabolic interactions.

Store tablets in dry, light-protected areas below 30°C. Pregnant/lactating women should use under medical supervision. Explore alternatives like Aceta 500 mg for different dosing needs.

Adults: 665 mg tablet every 8 hours (max 4g/day). Children (12+ years): 1 tablet every 8 hours. Dose adjustment needed in renal/hepatic impairment. Take with/without food. Do not crush. Consult doctor if fever persists beyond 3 days.

Side effects of Aceta Extend are usually mild, though haematological reactions including thrombocytopenia, leucopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. Pancreatitis, skin rashes, and other allergic reactions occur occasionally.

Pregnancy Category B. Safe during lactation in therapeutic doses. Avoid excessive use.

Monitor liver function in hepatic patients. Check serum creatinine with chronic use. Contraindicated in chronic alcoholics.

Pediatrics: Extended-release form contraindicated <12 years. Elderly: Dose adjustment needed. Hepatic/renal impairment: Reduce dose by 50%.

Liver damage is possible in adults who have taken 10 g or more of Aceta Extend. Ingestion of 5 g or more of Aceta Extend may lead to liver damage if the patient has following risk factors: If the patient is on long term treatment with Carbamazepine, Phenobarbitone, Phenytoin, Primidone, Rifampicin, St John’s Wort or other drugs that induce liver enzymes, or regularly consumes Ethanol in excess of recommended amounts, or is likely to be Glutathione deplete e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.

Symptoms: Symptoms of Aceta Extend overdose in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema and death. Acute renal failure with acute tubular necrosis, strongly suggested by loin pain, haematuria and proteinuria, may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported. Immediate treatment is essential in the management of Aceta Extend overdose. Treatment with activated charcoal should be considered if the overdose has been taken within 1 hour. Plasma Aceta Extend concentration should be measured at 4 hours or later after ingestion (earlier concentrations are unreliable). Treatment with N-acetylcysteine may be used up to 24 hours after ingestion of Aceta Extend. However, the maximum protective effect is obtained up to 8 hours post-ingestion. The effectiveness of the antidote declines sharply after this time. If required the patient should be given intravenous N-acetylcysteine, in line with the established dosage schedule. If vomiting is not a problem, oral Methionine may be a suitable alternative for remote areas, outside hospital. Management of patients who present with serious hepatic dysfunction beyond 24 hours from ingestion should be discussed with the NPIS or a liver unit.